TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05207098

Intervention type: OTHER
Intervention: Neurocognitive Tests
Description: Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery

Intervention type: OTHER
Intervention: Questionnaires
Description: Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
Study: NCT05631548

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS to dmPFC
Description: TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS to dmPFC
Description: TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham iTBS
Description: Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
Study: NCT05250193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DK ScoreTM Coronary Scoring Balloon
Description: After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Slip Element Coronary Dilatation Catheter
Description: After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
Study: NCT05677191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail
Description: open reduction

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Dual Mobility Arthroplasty
Description: Hip Arthroplasty Surgery
Study: NCT05551598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: IV, once every 12 weeks (Q12W)
Study: NCT06206824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucettinib-21
Description: See arm's description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucettinib-21
Description: See arm's description.
Study: NCT05551598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: IV, once every 12 weeks (Q12W)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: IV, once every 12 weeks (Q12W)
Study: NCT05628025

Intervention type: OTHER
Intervention: Organ phantom of prostate
Description: Participants will operate on a 3D printed model of the prostate.

Intervention type: OTHER
Intervention: Organ phantom of prostate
Description: Participants will operate on a 3D printed model of the prostate.
Study: NCT05429554

Intervention type: DRUG
Intervention: Vildagliptin
Description: observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
Study: NCT05122546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib S-malate
Description: Given PO
Study: NCT05123677

Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal ophthalmic artery doppler
Description: Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
Study: NCT04989777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABP (Intra-aortic balloon pump ) implantation
Description: Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
Study: NCT05122546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum CBM 588 Probiotic Strain
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study: NCT06102408

Intervention type: OTHER
Intervention: second line investigations for uveitis etiological workup
Description: Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

Intervention type: OTHER
Intervention: second line investigations for uveitis etiological workup
Description: Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

Intervention type: OTHER
Intervention: second line investigations for uveitis etiological workup
Description: Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
Study: NCT05222542

Intervention type: OTHER
Intervention: Sampling of plasma and cerebrospinal fluid at specified time points
Description: Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
Study: NCT05343598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head.
Study: NCT06103149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress(MIED)
Description: The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
Study: NCT05613517

Intervention type: OTHER
Intervention: Eye examination
Description: * orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~* ocular biometry~* corneal topography~* monocular photographs in photopic condition
Study: NCT05880121

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: brain MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: brain MRI
Study: NCT01211782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caprylic triglyceride
Description: oral, 20 gm, daily x 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: long-chain triglyceride
Description: oral, 14 gm, daily x 6 months
Study: NCT06312514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LAFIYA
Description: The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LAFIYA
Description: The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.
Study: NCT05496777

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Home-based prehabilitation program
Description: The home-based prehabilitation program will consist of a four-week program, where patients are expected to perform a high-intensity interval training on a home-trainer combined with functional mobility training three times a week. The program is partly supervised by a trained physiotherapist.
Study: NCT04242147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD033 (SAR445710)
Description: Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD033 (SAR445710)
Description: Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD033 (SAR445710)
Description: Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
Study: NCT06089993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal.
Study: NCT05419856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4P-004
Description: single intraarticular administration in the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4P-004
Description: single intraarticular administration in the knee joint
Study: NCT05404776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placement of Foley balloon for cervical ripening with tension.
Description: A Foley balloon will be placed for cervical ripening with tension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placement of Foley balloon for cervical ripening without tension.
Description: A Foley balloon will be placed for cervical ripening without tension.
Study: NCT05419856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4P-004
Description: single intraarticular administration in the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4P-004
Description: single intraarticular administration in the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intraarticular administration in the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intraarticular administration in the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intraarticular administration in the knee joint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single intraarticular administration in the knee joint
Study: NCT06311591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jaspr App
Description: Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.
Study: NCT06477848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Health System with SUD Resources
Description: This is a system-level intervention designed to improve collaboration among personnel from primary care clinics and SUD resources.
Study: NCT05622578

Intervention type: OTHER
Group type: OTHER
Intervention: QST, CPM and Paisudoscan
Description: Quantified pain tests

Intervention type: OTHER
Group type: OTHER
Intervention: QST, CPM and Paisudoscan
Description: Quantified pain tests
Study: NCT05500105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention
Description: Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory.
Study: NCT06009536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Achilles Tendon Loading Exercise Protocol According to Silbernagel
Description: It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
Study: NCT05722587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain science education
Description: High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
Study: NCT06145594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMA Monitoring
Description: Weekly prompts to participants' smart phones for collection of PHQ-9 data
Study: NCT06126965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-（5%） BID
Description: Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
Study: NCT06145594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMA Monitoring
Description: Weekly prompts to participants' smart phones for collection of PHQ-9 data

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduling Maintenance TMS sessions
Description: When threshold score is reached, the participants is offered TMS maintenance treatments
Study: NCT06387082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-506
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-506
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-506
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-506
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-506
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.